Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,056 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Microglial cannabinoid receptor type II stimulation improves cognitive impairment and neuroinflammation in Alzheimer's disease mice by controlling astrocyte activation.
Sobue A, Komine O, Endo F, Kakimi C, Miyoshi Y, Kawade N, Watanabe S, Saito Y, Murayama S, Saido TC, Saito T, Yamanaka K. Sobue A, et al. Among authors: miyoshi y. Cell Death Dis. 2024 Nov 26;15(11):858. doi: 10.1038/s41419-024-07249-6. Cell Death Dis. 2024. PMID: 39587077 Free PMC article.
Efficacy of a melatonin receptor agonist and orexin receptor antagonists in preventing delirium symptoms in the olderly patients with stroke: a retrospective study.
Miyoshi Y, Shigetsura Y, Hira D, Maki T, Kawashima H, Sugita N, Sugawara N, Kitada N, Hirai M, Kawata M, Endo H, Kojima Y, Ikuta K, Katsube Y, Imayoshi N, Nakagawa S, Tsuda M, Terada T. Miyoshi Y, et al. J Pharm Health Care Sci. 2024 Nov 18;10(1):74. doi: 10.1186/s40780-024-00397-z. J Pharm Health Care Sci. 2024. PMID: 39558437 Free PMC article.
Low remission rates and high incidence of adverse events in a prospective VEXAS syndrome registry.
Kirino Y, Maeda A, Asano T, Migita K, Hidaka Y, Ida H, Kobayashi D, Oda N, Rokutanda R, Fujieda Y, Atsumi T, Kishida D, Kobayashi H, Shiratsuchi M, Shimizu T, Kawakami A, Tanaka K, Tsuji T, Mishima K, Miyamae T, Hasegawa A, Ikeda K, Watanabe T, Yamaguchi Y, Nishikomori R, Ohara O, Nakajima H; Japan VEXAS study group. Kirino Y, et al. Rheumatology (Oxford). 2024 Sep 28:keae530. doi: 10.1093/rheumatology/keae530. Online ahead of print. Rheumatology (Oxford). 2024. PMID: 39340799
A randomized, double-blind, placebo-controlled phase II study of olanzapine-based prophylactic antiemetic therapy for delayed and persistent nausea and vomiting in patients with HER2-positive or HER2-low breast cancer treated with trastuzumab deruxtecan: ERICA study (WJOG14320B).
Sakai H, Tsurutani J, Ozaki Y, Ishiguro H, Nozawa K, Yamanaka T, Aogi K, Matsumoto K, Iwasa T, Tokiwa M, Tsuneizumi M, Miyoshi Y, Kitagawa C, Yamamoto M, Takano Y, Imamura CK, Chiba Y, Takiguchi D, Ezumi T, Takano T. Sakai H, et al. Among authors: miyoshi y. Ann Oncol. 2024 Sep 14:S0923-7534(24)03995-4. doi: 10.1016/j.annonc.2024.09.001. Online ahead of print. Ann Oncol. 2024. PMID: 39284382 Free article.
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer.
Schmid P, Cortes J, Dent R, McArthur H, Pusztai L, Kümmel S, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Im SA, Untch M, Fasching PA, Mouret-Reynier MA, Foukakis T, Ferreira M, Cardoso F, Zhou X, Karantza V, Tryfonidis K, Aktan G, O'Shaughnessy J; KEYNOTE-522 Investigators. Schmid P, et al. N Engl J Med. 2024 Nov 28;391(21):1981-1991. doi: 10.1056/NEJMoa2409932. Epub 2024 Sep 15. N Engl J Med. 2024. PMID: 39282906 Clinical Trial.
1,056 results